India’s Biocon (BSE: 532523), a leading biosimilars and generics drugmaker, saw its shares gain 4.8% to 464.30 rupees by midday today, after it announced its first generic formulation approval to make rosuvastatin calcium tablets in the European Union.
The drug is a copy version on Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) blockbuster cholesterol lowerer Crestor. Biocon says launch of its generic in Europe is planned for 2017. Biocon also plans to file an Abbreviated New Drug Application for its generic in the USA.
Sees $1.2 billion market opportunity
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze